RU2011133891A - СПОСОБ ЛЕЧЕНИЯ АСТМЫ (ВАРИАНТЫ) И СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИЙ ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА - Google Patents
СПОСОБ ЛЕЧЕНИЯ АСТМЫ (ВАРИАНТЫ) И СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИЙ ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА Download PDFInfo
- Publication number
- RU2011133891A RU2011133891A RU2011133891/15A RU2011133891A RU2011133891A RU 2011133891 A RU2011133891 A RU 2011133891A RU 2011133891/15 A RU2011133891/15 A RU 2011133891/15A RU 2011133891 A RU2011133891 A RU 2011133891A RU 2011133891 A RU2011133891 A RU 2011133891A
- Authority
- RU
- Russia
- Prior art keywords
- methylbutyrate
- hydroxy
- cytokines
- interleukin
- type
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
1. Способ лечения астмы у индивидуума, характеризующейся дисбалансом содержания цитокинов первого и второго типов, который включает введение индивидууму β-гидрокси-β-метилбутирата в количестве, эффективном для модуляции дисбаланса продукции цитокинов первого и второго типов.2. Способ по п.1, в котором отношение содержания цитокинов первого типа к содержанию цитокинов второго типа возрастает в результате введения β-гидрокси-β-метилбутирата.3. Способ по п.2, в котором содержание цитокинов первого типа возрастает без повышения содержания цитокинов второго типа.4. Способ по п.2, в котором эффективное количество β-гидрокси-β-метилбутирата находится в пределах от приблизительно 0,5 до приблизительно 10 г в день.5. Способ по п.2, в котором β-гидрокси-β-метилбутират вводится в составе питательного продукта, который дополнительно содержит по меньшей мере один жир и/или белок и/или углевод.6. Способ по п.2, в котором цитокины типа 1 выбраны из группы, включающей интерферон y, интерлейкин 2 и интерлейкин 12, а цитокины типа 2 выбраны из группы, включающей интерлейкин 4, интерлейкин 5, интерлейкин 13 и интерлейкин 10.7. Способ по п.1, в котором количество β-гидрокси-β-метилбутирата является эффективным для предотвращения уменьшения значения FEV.8. Способ по п.1, в котором количество β-гидрокси-β-метилбутирата является эффективным для поддержания базового значения FEVвыше 80%.9. Способ по п.1, в котором цитокины типа 1 представляют собой интерфероны или интерлейкин 2, а цитокины типа 2 представляют собой интерлейкин 4.10. Способ лечения астмы у индивидуума, относящегося к группе риска в отношении развития астмы, включающий введение указанному индивид
Claims (15)
1. Способ лечения астмы у индивидуума, характеризующейся дисбалансом содержания цитокинов первого и второго типов, который включает введение индивидууму β-гидрокси-β-метилбутирата в количестве, эффективном для модуляции дисбаланса продукции цитокинов первого и второго типов.
2. Способ по п.1, в котором отношение содержания цитокинов первого типа к содержанию цитокинов второго типа возрастает в результате введения β-гидрокси-β-метилбутирата.
3. Способ по п.2, в котором содержание цитокинов первого типа возрастает без повышения содержания цитокинов второго типа.
4. Способ по п.2, в котором эффективное количество β-гидрокси-β-метилбутирата находится в пределах от приблизительно 0,5 до приблизительно 10 г в день.
5. Способ по п.2, в котором β-гидрокси-β-метилбутират вводится в составе питательного продукта, который дополнительно содержит по меньшей мере один жир и/или белок и/или углевод.
6. Способ по п.2, в котором цитокины типа 1 выбраны из группы, включающей интерферон y, интерлейкин 2 и интерлейкин 12, а цитокины типа 2 выбраны из группы, включающей интерлейкин 4, интерлейкин 5, интерлейкин 13 и интерлейкин 10.
7. Способ по п.1, в котором количество β-гидрокси-β-метилбутирата является эффективным для предотвращения уменьшения значения FEV1.
8. Способ по п.1, в котором количество β-гидрокси-β-метилбутирата является эффективным для поддержания базового значения FEV1 выше 80%.
9. Способ по п.1, в котором цитокины типа 1 представляют собой интерфероны или интерлейкин 2, а цитокины типа 2 представляют собой интерлейкин 4.
10. Способ лечения астмы у индивидуума, относящегося к группе риска в отношении развития астмы, включающий введение указанному индивидууму эффективного количества β-гидрокси-β-метилбутирата.
11. Способ по п.10, в котором β-гидрокси-β-метилбутират вводят в составе питательного продукта, который дополнительно содержит по меньшей мере один жир и/или белок и/или углевод.
12. Способ по п.11, в котором эффективное количество β-гидрокси-β-метилбутирата находится в пределах от приблизительно 0,5 до приблизительно 10 г в день.
13. Способ снижения риска развития инфекций у индивидуума пожилого возраста, относящегося к группе риска в отношении указанных инфекций, который включает введение указанному индивидууму эффективного количества β-гидрокси-β-метилбутирата.
14. Способ по п.13, в котором β-гидрокси-β-метилбутират вводят в составе питательного продукта, который дополнительно содержит по меньшей мере один жир и/или белок и/или углевод.
15. Способ по п.14, в котором эффективное количество β-гидрокси-β-метилбутирата находится в пределах от приблизительно 0,5 до приблизительно 10 г в день.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75225305P | 2005-12-19 | 2005-12-19 | |
| US60/752,253 | 2005-12-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008129605/15A Division RU2469719C2 (ru) | 2005-12-19 | 2006-12-19 | СПОСОБ ЛЕЧЕНИЯ АЛЛЕРГИИ, СПОСОБ ЛЕЧЕНИЯ АСТМЫ, СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИИ И СПОСОБ ЛЕЧЕНИЯ СОСТОЯНИЯ, ХАРАКТЕРИЗУЮЩЕГОСЯ ДИСБАЛАНСОМ СОДЕРЖАНИЯ ЦИТОКИНОВ ТИПОВ 1 И 2, ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011133891A true RU2011133891A (ru) | 2013-02-20 |
Family
ID=38066532
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008129605/15A RU2469719C2 (ru) | 2005-12-19 | 2006-12-19 | СПОСОБ ЛЕЧЕНИЯ АЛЛЕРГИИ, СПОСОБ ЛЕЧЕНИЯ АСТМЫ, СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИИ И СПОСОБ ЛЕЧЕНИЯ СОСТОЯНИЯ, ХАРАКТЕРИЗУЮЩЕГОСЯ ДИСБАЛАНСОМ СОДЕРЖАНИЯ ЦИТОКИНОВ ТИПОВ 1 И 2, ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА |
| RU2011133891/15A RU2011133891A (ru) | 2005-12-19 | 2011-08-12 | СПОСОБ ЛЕЧЕНИЯ АСТМЫ (ВАРИАНТЫ) И СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИЙ ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008129605/15A RU2469719C2 (ru) | 2005-12-19 | 2006-12-19 | СПОСОБ ЛЕЧЕНИЯ АЛЛЕРГИИ, СПОСОБ ЛЕЧЕНИЯ АСТМЫ, СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИИ И СПОСОБ ЛЕЧЕНИЯ СОСТОЯНИЯ, ХАРАКТЕРИЗУЮЩЕГОСЯ ДИСБАЛАНСОМ СОДЕРЖАНИЯ ЦИТОКИНОВ ТИПОВ 1 И 2, ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US8778992B2 (ru) |
| EP (2) | EP2082738B1 (ru) |
| JP (2) | JP5227182B2 (ru) |
| CN (2) | CN101374509B (ru) |
| AU (1) | AU2006331950A1 (ru) |
| BR (1) | BRPI0620083A2 (ru) |
| CA (1) | CA2632262C (ru) |
| CR (1) | CR10085A (ru) |
| EC (1) | ECSP088539A (ru) |
| ES (2) | ES2548305T3 (ru) |
| MY (1) | MY180733A (ru) |
| NZ (2) | NZ593182A (ru) |
| RU (2) | RU2469719C2 (ru) |
| SV (1) | SV2009002948A (ru) |
| TW (1) | TWI424840B (ru) |
| WO (1) | WO2007075605A2 (ru) |
| ZA (1) | ZA200805297B (ru) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| JP5227182B2 (ja) | 2005-12-19 | 2013-07-03 | アボット・ラボラトリーズ | １型および２型サイトカイン産生における不均衡を調節するためのベータ−ヒドロキシ−ベータ−メチルブチラートの使用 |
| RU2536291C2 (ru) | 2008-12-04 | 2014-12-20 | Массачусетс Инститьют Оф Текнолоджи | Способ диагностики аллергических реакций |
| US9404924B2 (en) | 2008-12-04 | 2016-08-02 | Massachusetts Institute Of Technology | Method of performing one-step, single cell RT-PCR |
| US9707241B2 (en) | 2008-12-09 | 2017-07-18 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US9539224B2 (en) | 2008-12-09 | 2017-01-10 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US9259430B2 (en) | 2008-12-09 | 2016-02-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| EP2381784B1 (en) * | 2008-12-09 | 2018-07-11 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US9770424B2 (en) | 2008-12-09 | 2017-09-26 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US11173167B2 (en) | 2008-12-09 | 2021-11-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| ES2700777T3 (es) * | 2009-07-03 | 2019-02-19 | Nutreco Nederland Bv | Pienso animal o comida para humanos para mejorar las propiedades de la barrera intestinal |
| PE20121727A1 (es) * | 2010-01-29 | 2013-01-13 | Abbott Lab | Liquidos nutricionales en envases plasticos que comprenden beta-hidroxi-beta-metilbutirato (hmb) |
| BR112012017683A2 (pt) * | 2010-01-29 | 2015-09-01 | Abbott Lab | Emulsões nutritivas compreendendo hmb de calcio e proteina soluvel |
| US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
| PE20121729A1 (es) | 2010-01-29 | 2013-01-16 | Abbott Lab | Emulsiones nutricionales que comprenden beta-hidroxi-beta-metilbutirato (hmb) de calcio |
| WO2011094548A1 (en) | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Aseptically packaged nutritional liquids comprising hmb |
| JP5892947B2 (ja) * | 2010-01-29 | 2016-03-23 | アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ | 噴霧乾燥ｈｍｂを含む栄養粉末 |
| TWI526161B (zh) * | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液 |
| EP2675298A1 (en) * | 2011-02-17 | 2013-12-25 | Abbott Laboratories | Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate |
| CN102524332A (zh) * | 2011-12-19 | 2012-07-04 | 北京康比特体育科技股份有限公司 | 一种减肥压缩饼干及其制备方法 |
| CA2868017A1 (en) * | 2012-03-19 | 2013-09-26 | Abbott Laboratories | Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance |
| WO2013188258A1 (en) * | 2012-06-11 | 2013-12-19 | Abbott Laboratories | Use of hmb to improve health outcomes for hospitalized patients |
| EP2895013A1 (en) * | 2012-09-17 | 2015-07-22 | Abbott Laboratories | Beta-hydroxy-beta-methylbutryic acid- containing compositions and uses thereof |
| US20140272000A1 (en) * | 2013-03-14 | 2014-09-18 | Metabolic Technologies, Inc. | Liquids and Foodstuffs Containing beta-hydroxy-beta-methylbutyrate (HMB) in the Free Acid Form and Methods of Manufacturing or Producing the Same |
| CA2904119C (en) | 2013-03-14 | 2018-01-02 | Abbott Laboratories | Treatment of insulin resistance associated with prolonged physical inactivity |
| CN105188417B (zh) * | 2013-03-15 | 2017-08-08 | 雅培制药有限公司 | 包括β‑羟基‑β‑甲基丁酸钙、酪蛋白磷酸肽和蛋白质的营养组合物 |
| EP3349745B1 (en) | 2015-09-16 | 2023-12-13 | Metabolic Technologies, LLC | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for enhancing recovery from soft tissue trauma |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| TWI775921B (zh) | 2017-08-14 | 2022-09-01 | 美商胺細拉健康公司 | 用於治療和高血氨症或肌肉耗損中之一者或兩者相關之肝疾病及失調之組合物及方法 |
| JP2021527670A (ja) | 2018-06-20 | 2021-10-14 | アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． | 筋肉中の脂肪浸潤の治療のための組成物及び方法 |
| JP7156683B2 (ja) * | 2018-09-28 | 2022-10-19 | 株式会社東洋新薬 | 経口組成物 |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3408210A (en) | 1965-06-14 | 1968-10-29 | Wilbert A. Heyman | Dehydration of foods |
| US3542560A (en) | 1967-12-06 | 1970-11-24 | American Home Prod | Infant formula with fat composition like human milk |
| GB1446965A (en) | 1974-02-14 | 1976-08-18 | Agricultural Vegetable Prod | Preparation of food products |
| US4104290A (en) | 1975-02-07 | 1978-08-01 | H.L.S. Ltd., Industrial Engineering Company | Process for separating oils and fats into liquid and solid fractions |
| US4311645A (en) * | 1980-03-24 | 1982-01-19 | Hoffmann-La Roche Inc. | Synthesis of SRS-active compounds |
| US4866040A (en) | 1986-01-06 | 1989-09-12 | Alfred Stracher | Aminocarnitine directed pharmaceutical agents |
| US4742081A (en) | 1986-01-06 | 1988-05-03 | Alfred Stracher | Carnitine coupled pharmaceutical agents |
| ES2052066T3 (es) | 1988-10-31 | 1994-07-01 | Sandoz Nutrition Ltd | Mejoras en o relacionadas con compuestos organicos. |
| US5000975A (en) | 1988-12-29 | 1991-03-19 | American Home Products Corporation | Randomized palm oil fat composition for infant formulas |
| CA2010511A1 (en) | 1989-03-01 | 1990-09-01 | Roberto L. Ceriani | Method of enhancing cancer therapy by administration of unsaturated fatty acids |
| US5457130A (en) | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
| US5028440A (en) | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
| US5087472A (en) | 1990-01-30 | 1992-02-11 | Iowa State University Research Foundation, Inc. | Feed compositions for domestics animals containing hydroxymethylbutyrate |
| US4992470A (en) | 1990-02-08 | 1991-02-12 | Iowa State University Research Foundation, Inc. | Method of enhancing immune response of mammals |
| US5167957A (en) | 1990-09-06 | 1992-12-01 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for the treatment of dietary deficiencies |
| US5601860A (en) | 1990-11-30 | 1997-02-11 | American Home Products Corporation | Corandomized fat compositions for infant formulas |
| KR100219771B1 (ko) | 1991-03-18 | 1999-10-01 | 이치로 키타사토 | 돼지용 사료 및 이를 사용하는 돼지 사육법 |
| US5171442A (en) | 1991-10-18 | 1992-12-15 | Nakshbendi Ghassan F | Water purification apparatus |
| US5223285A (en) | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
| NZ256300A (en) | 1992-09-16 | 1997-06-24 | Univ Iowa State Res Found Inc | Administration of beta-hydroxy-beta-methyl butyric acid, or its convertible forms, to lower cholesterol levels |
| US5447732A (en) | 1992-11-25 | 1995-09-05 | Ajinomoto Co., Inc. | High-absorption mineral-containing composition and foods |
| US5348979A (en) | 1992-12-23 | 1994-09-20 | Iowa State University Research Foundation Inc. | Method of promoting nitrogen retention in humans |
| JP2761294B2 (ja) | 1993-05-13 | 1998-06-04 | ロデルス−クロクラーン | エステル交換トリグリセリドブレンド由来のヒト母乳脂肪代用品 |
| US6136858A (en) | 1994-01-10 | 2000-10-24 | Abbott Laboratories | Infant formula and methods of improving infant stool patterns |
| US5444054A (en) | 1994-04-01 | 1995-08-22 | Abbott Labatories | Method of treating ulcerative colitis |
| US5780451A (en) | 1994-04-01 | 1998-07-14 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
| US5952314A (en) | 1994-04-01 | 1999-09-14 | Demichele; Stephen Joseph | Nutritional product for a person having ulcerative colitis |
| US5576287A (en) | 1994-04-29 | 1996-11-19 | Wake Forest University | Method for treating acute renal disease and failure |
| US5726146A (en) | 1994-12-06 | 1998-03-10 | Natural Supplement Association, Incorporated | Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass |
| KR0140248B1 (ko) | 1995-03-23 | 1998-06-15 | 한상기 | 신규한 카제인 포스포펩티드, 그것을 포함하는 카제인 및 그 제조방법 |
| DE19528461A1 (de) | 1995-08-03 | 1997-02-06 | Braun Melsungen Ag | Präparat zur Ernährung |
| US5641531A (en) | 1995-09-28 | 1997-06-24 | Abbott Laboratories | Nutritional liquid supplement beverage and method of making same |
| US6165518A (en) | 1996-04-11 | 2000-12-26 | Loders Croklaan B.V. | Free flowing fat compositions |
| US6077828A (en) | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| US5756469A (en) | 1996-07-26 | 1998-05-26 | Beale; Paxton K. | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal |
| US7504376B2 (en) | 1996-08-12 | 2009-03-17 | Natural Alternatives International | Methods and compositions for increasing the anaerobic working capacity in tissues |
| US6080788A (en) | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
| DE29707308U1 (de) | 1997-04-23 | 1997-06-26 | Kunz Armin | Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus |
| US6660258B1 (en) | 1997-05-09 | 2003-12-09 | Pharma Pacific Pty Ltd | Oromucosal cytokine compositions and uses thereof |
| US6103764A (en) | 1997-11-07 | 2000-08-15 | Iowa State University Research Foundation, Inc. | Method for increasing the aerobic capacity of muscle |
| US6475539B1 (en) | 1998-05-07 | 2002-11-05 | Abbott Laboratories | Nutritionally complete low pH enteral formula |
| JP4175698B2 (ja) | 1998-06-19 | 2008-11-05 | サントリー株式会社 | 新規なトリグリセリド及びそれを含む組成物 |
| US6031000A (en) | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
| WO2000006134A2 (en) | 1998-07-30 | 2000-02-10 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity |
| US5976550A (en) | 1998-11-20 | 1999-11-02 | Engel; Peter H. | Dietary food supplement |
| US20010008641A1 (en) | 1998-11-25 | 2001-07-19 | R. Douglas Krotzer | Nutritionally active composition for bodybuilding |
| US6294206B1 (en) | 1999-04-09 | 2001-09-25 | Abbott Laboratories | Powdered human milk fortifier |
| US6291525B1 (en) | 1999-09-08 | 2001-09-18 | Iowa State University Research Foundation, Inc. | Method for improving a human's perception of his emotional state |
| WO2001028356A2 (en) | 1999-10-18 | 2001-04-26 | Muscletech Research And Development Inc. | Food supplement for increasing lean mass and strength |
| GB9929919D0 (en) | 1999-12-17 | 2000-02-09 | Hannah Research Inst The | Calcium phosphate nanoclusters and their applications |
| US6521591B1 (en) | 2000-02-10 | 2003-02-18 | N.V. Nutricia | Pharmaceutical composition for muscular anabolism |
| US7250397B2 (en) | 2000-02-23 | 2007-07-31 | Zealand Pharma A/S | Antiarrhythmic peptides |
| CA2404799C (en) | 2000-04-06 | 2007-08-07 | Conlinco, Inc. | Conjugated linoleic acid compositions |
| JP4625156B2 (ja) | 2000-04-10 | 2011-02-02 | イーエヌ大塚製薬株式会社 | 癌化学療法に伴う副作用軽減剤 |
| US6420342B1 (en) | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
| US20050106219A1 (en) | 2000-05-30 | 2005-05-19 | Karlheinz Bortlik | Primary composition comprising a lipophilic bioactive compound |
| CN100475266C (zh) | 2000-08-03 | 2009-04-08 | 北卡罗来纳州大学 | 经卵内喂养增强卵生物种的发育 |
| DE50106272D1 (de) | 2000-08-29 | 2005-06-23 | Lonza Ag | Verfahren zur herstellung einer granulierbaren mischung und carnitin-magnesium-hydroxycitrat |
| US20030203070A1 (en) | 2000-09-26 | 2003-10-30 | The Procter & Gamble Company | Compositions containing sorbitan monoesters |
| EP1198991B1 (en) | 2000-10-20 | 2012-12-19 | Nutriz N.V: | Non-dairy products derived from rice |
| DE60219600T2 (de) | 2001-02-15 | 2007-12-20 | Adeka Corp. | PRODUKTE ENTHALTEND G(b)-Glucan |
| JP3735070B2 (ja) | 2001-03-26 | 2006-01-11 | 花王株式会社 | 容器詰乳化飲料 |
| US6620427B2 (en) | 2001-04-24 | 2003-09-16 | Abbott Laboratories | Method for improving bone mineralization |
| US20030021877A1 (en) | 2001-06-13 | 2003-01-30 | Cain Frederick William | Micronised fat particles |
| DE10145818C1 (de) | 2001-09-17 | 2002-10-10 | Alfill Engineering Gmbh & Co K | Sterilisiervorrichtung mit H202-Verdampfer |
| GB2381451A (en) | 2001-11-01 | 2003-05-07 | New Technology Res Ltd | Pharmaco-dietary preparation having nutrition-supplementing and nutrition-enhancing effect |
| JP2003137790A (ja) | 2001-11-01 | 2003-05-14 | Mie Kariyou Kk | β−２，１（β２→β１）結合連鎖フラクトースオリゴマーを含有するフラクトオリゴ糖を有効成分とする医薬 |
| US7419596B2 (en) | 2001-12-12 | 2008-09-02 | Martek Biosciences Corporation | Extraction and winterization of lipids from oilseed and microbial sources |
| US7168581B2 (en) | 2001-12-21 | 2007-01-30 | Rexam Medical Packaging Inc. | Closure for a retort processed container having a peelable seal |
| DE10163676A1 (de) * | 2001-12-21 | 2003-07-10 | Phenion Gmbh & Co Kg | Verwendung von Hyperforin oder Extrakten aus Johanniskraut gegen anaphylaktische Schockzustände oder Osteoporose |
| JP4497930B2 (ja) * | 2002-04-23 | 2010-07-07 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | インターロイキン−４遺伝子発現抑制剤としての３−置換アミノ−１Ｈ−インドール−２−カルボン酸および３−置換アミノ−ベンゾ（ｂ）チオフェン−２−カルボン酸誘導体 |
| SE0201581D0 (sv) | 2002-05-29 | 2002-05-29 | Scandinavian Biotechnology Res | New improved acyltransferase |
| AU2003251557A1 (en) | 2002-06-28 | 2004-01-19 | Richard C. Theuer | Fat compositions for infant formula and methods therefor |
| US20040048925A1 (en) | 2002-09-09 | 2004-03-11 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
| US20040106678A1 (en) | 2002-09-17 | 2004-06-03 | Dobbins Thomas A | Compositions for the parenteral administration of calcium and magnesium |
| US7411039B2 (en) | 2002-10-14 | 2008-08-12 | Novo Nordisk A/S | GLP-2 compounds, formulations, and uses thereof |
| US7445807B2 (en) | 2002-10-15 | 2008-11-04 | Western Holdings, Llc | Agglomerated granular protein-rich nutritional supplement |
| GB0301554D0 (en) * | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
| US7332178B2 (en) | 2003-04-25 | 2008-02-19 | Abbott Laboratories | Stable nutritional powder containing ascorbyl palmitate |
| FR2856596B1 (fr) | 2003-06-27 | 2007-04-27 | Bioprojet Soc Civ | Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes. |
| CA2542612A1 (en) | 2003-10-14 | 2005-04-21 | Kingston Henry Gordon Mills | Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease |
| IL158555A0 (en) | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Human breast milk lipid mimetic as dietary supplement |
| WO2005060952A1 (en) | 2003-12-24 | 2005-07-07 | N.V. Nutricia | Compositions comprising pantothenic acid or derivatives thereof and their use for stimulating appetite |
| US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| US20050249650A1 (en) | 2004-05-07 | 2005-11-10 | Fmc Technologies, Inc. | Immersion retort |
| ATE492170T1 (de) | 2004-09-09 | 2011-01-15 | Nestec Sa | Herstellungsmethoden für nahrungsmittel mit verbesserter qualität |
| WO2006031699A2 (en) | 2004-09-10 | 2006-03-23 | Diversa Corporation | Compositions and methods for making and modifying oils |
| PL371081A1 (pl) | 2004-11-08 | 2006-05-15 | Sgp & Sons Ab | Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt |
| US8067052B2 (en) | 2005-02-25 | 2011-11-29 | Siddharth Shastri | Nutritional composition and a container for the convenient transport and storage of the nutritional composition |
| CA2537452C (en) | 2005-03-09 | 2013-12-24 | Abbott Laboratories | Concentrated human milk fortifier liquid |
| RU2413430C2 (ru) | 2005-04-27 | 2011-03-10 | Энзимотек Лтд. | Композиция жировой основы (варианты) и способ ее получения (варианты), композиция заменителя жира женского молока и способ ее получения (варианты), смесь для детского питания |
| CA2606300A1 (en) | 2005-06-06 | 2006-12-14 | Bristol-Myers Squibb Company | Low-phytate infant formulas |
| RU2385647C2 (ru) | 2005-08-26 | 2010-04-10 | Нестек С.А. | Питание для пациентов, страдающих ожирением |
| MY147363A (en) | 2005-09-20 | 2012-11-30 | Nestec Sa | Water dispersible composition and method for preparing same |
| EP1968402A2 (en) | 2005-10-07 | 2008-09-17 | Ocean Nutrition Canada Limited | Salts of fatty acids and methods of making and using thereof |
| EP1973426A2 (en) | 2005-11-03 | 2008-10-01 | Southwest Immunology Inc. | Compositions for preventing and reducing delayed onset muscle soreness |
| JP5227182B2 (ja) | 2005-12-19 | 2013-07-03 | アボット・ラボラトリーズ | １型および２型サイトカイン産生における不均衡を調節するためのベータ−ヒドロキシ−ベータ−メチルブチラートの使用 |
| ATE475328T1 (de) | 2006-01-31 | 2010-08-15 | Nestec Sa | Nährstoffzusammensetzung für säuglinge mit niedrigem geburtsgewicht |
| US20080119552A1 (en) | 2006-11-17 | 2008-05-22 | Novus International Inc. | Matrix-embedded compositions having organic acids and fatty acids |
| US20080194407A1 (en) | 2007-02-14 | 2008-08-14 | Ashmead H Dewayne | High nitrogen containing chelate compositions suitable for plant delivery |
| US20090110674A1 (en) | 2007-10-24 | 2009-04-30 | Loizou Nicos C | Health supplement |
| CA2649477C (en) | 2008-04-18 | 2016-04-19 | Nuvocare Health Sciences Inc. | Composition and method for promoting internal health and external appearance |
| CA2723441A1 (en) | 2008-05-21 | 2009-11-26 | Stokely-Van Camp, Inc. | Milk-based recovery beverage |
| EP2381784B1 (en) | 2008-12-09 | 2018-07-11 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| JP2009155336A (ja) | 2009-03-31 | 2009-07-16 | Tsujido Chemical Corp | 治療剤 |
| US20090312419A1 (en) | 2009-08-12 | 2009-12-17 | Kneller Bruce W | CREATINE -ßALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE |
| PL217815B1 (pl) | 2009-12-14 | 2014-08-29 | Olimp Lab Spółka Z Ograniczoną Odpowiedzialnością | Napój izotoniczny z chelatami |
| CN101785566A (zh) | 2010-01-22 | 2010-07-28 | 北京康比特体育科技股份有限公司 | 一种含有hmb的运动饮料 |
| PE20121729A1 (es) | 2010-01-29 | 2013-01-16 | Abbott Lab | Emulsiones nutricionales que comprenden beta-hidroxi-beta-metilbutirato (hmb) de calcio |
| TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液 |
| US10869843B2 (en) | 2010-11-23 | 2020-12-22 | Chemi Nutra | Method for increasing muscle mass and strength |
| BR112013016351A2 (pt) | 2010-12-27 | 2018-06-26 | Abbott Lab | Métodos para facilitar recuperação muscular após um período de desuso empregando o beta- hidróxi-beta-metilbutirato |
| WO2012097061A1 (en) | 2011-01-13 | 2012-07-19 | Abbott Laboratories | Nutritional compositions and methods for improving skeletal muscle protein metabolism |
| TW201320908A (zh) | 2011-10-13 | 2013-06-01 | Abbott Lab | 包含β－丙胺酸之營養產品 |
| WO2013170189A1 (en) | 2012-05-11 | 2013-11-14 | Abbott Laboratories | Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow |
| WO2013188258A1 (en) | 2012-06-11 | 2013-12-19 | Abbott Laboratories | Use of hmb to improve health outcomes for hospitalized patients |
-
2006
- 2006-12-19 JP JP2008547409A patent/JP5227182B2/ja not_active Expired - Fee Related
- 2006-12-19 WO PCT/US2006/048303 patent/WO2007075605A2/en active Application Filing
- 2006-12-19 RU RU2008129605/15A patent/RU2469719C2/ru not_active IP Right Cessation
- 2006-12-19 CA CA2632262A patent/CA2632262C/en not_active Expired - Fee Related
- 2006-12-19 US US11/641,978 patent/US8778992B2/en not_active Expired - Fee Related
- 2006-12-19 NZ NZ593182A patent/NZ593182A/xx not_active IP Right Cessation
- 2006-12-19 ES ES09156851.9T patent/ES2548305T3/es active Active
- 2006-12-19 ES ES06845745.6T patent/ES2548432T3/es active Active
- 2006-12-19 CN CN2006800479363A patent/CN101374509B/zh not_active Expired - Fee Related
- 2006-12-19 MY MYPI20082097A patent/MY180733A/en unknown
- 2006-12-19 NZ NZ568611A patent/NZ568611A/en not_active IP Right Cessation
- 2006-12-19 EP EP09156851.9A patent/EP2082738B1/en not_active Expired - Fee Related
- 2006-12-19 BR BRPI0620083-4A patent/BRPI0620083A2/pt not_active IP Right Cessation
- 2006-12-19 CN CN2011100849630A patent/CN102225060A/zh active Pending
- 2006-12-19 EP EP06845745.6A patent/EP1968564B1/en not_active Expired - Fee Related
- 2006-12-19 AU AU2006331950A patent/AU2006331950A1/en not_active Abandoned
- 2006-12-19 TW TW095147808A patent/TWI424840B/zh not_active IP Right Cessation
-
2008
- 2008-06-16 EC EC2008008539A patent/ECSP088539A/es unknown
- 2008-06-18 CR CR10085A patent/CR10085A/es unknown
- 2008-06-18 ZA ZA200805297A patent/ZA200805297B/xx unknown
- 2008-06-19 SV SV2008002948A patent/SV2009002948A/es unknown
-
2011
- 2011-08-12 RU RU2011133891/15A patent/RU2011133891A/ru not_active Application Discontinuation
-
2012
- 2012-01-11 US US13/347,757 patent/US20120178811A1/en not_active Abandoned
- 2012-01-11 US US13/347,750 patent/US8796333B2/en not_active Expired - Fee Related
- 2012-01-11 US US13/347,774 patent/US20120177744A1/en not_active Abandoned
-
2013
- 2013-01-24 JP JP2013010874A patent/JP5696168B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011133891A (ru) | СПОСОБ ЛЕЧЕНИЯ АСТМЫ (ВАРИАНТЫ) И СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИЙ ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА | |
| Lönnerdal | Nutritional roles of lactoferrin | |
| Inagaki-Ohara et al. | Intestinal intraepithelial lymphocytes sustain the epithelial barrier function against Eimeria vermiformis infection | |
| DE60127457D1 (de) | Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen | |
| Aviles et al. | Active hexose correlated compound enhances the immune function of mice in the hindlimb-unloading model of spaceflight conditions | |
| Rochell et al. | Effects of dietary soybean meal concentration on growth and immune response of pigs infected with porcine reproductive and respiratory syndrome virus | |
| Michele et al. | Vitamin supplements in the Era of SARS-Cov2 pandemic | |
| KR20200024940A (ko) | 의약품, 보충제 및 섭취된 물질의 생체 이용률을 향상시키기 위한 조성물 | |
| JP3392668B2 (ja) | ゴマリグナン物質とビタミンｅ類の強化卵、強化卵の製造法、および強化卵に基づく健康食品 | |
| US3347742A (en) | 2-(4-cyclohexylcyclohexyl)-3-hydroxy-1, 4-naphthoquinone in controlling coccidiosis in poultry | |
| Sarker et al. | Keyhole limpet hemocyanin augmented the killing activity, cytokine production and proliferation of NK cells, and inhibited the proliferation of Meth A sarcoma cells in vitro | |
| Kobayashi et al. | Dietary supplementation of soybean kunitz trypsin inhibitor reduces lipopolysaccharide-induced lethality in mouse model | |
| Wu et al. | Major royal-jelly proteins intake modulates immune functions and gut microbiota in mice | |
| EP3174548B1 (en) | Marine peptides and fish nucleotides, compositions and uses thereof for reducing blood glucose | |
| CN107029214A (zh) | 一种调节肠道微生物的组合物及其制备方法 | |
| JPH08503001A (ja) | 免疫組織および免疫反応強化化合物 | |
| Cameron et al. | Chronic hepatitis treated with methionine and choline | |
| ATE258550T1 (de) | Oxirancarbonsäuren für die behandlung von diabetes | |
| DK1100463T3 (da) | Injicerbare formuleringer indeholdende ramoplanin | |
| Miranda-Massari et al. | Expediting COVID-19 Recovery with an Orthomolecular Approach: Two Case Reports | |
| ATE405584T1 (de) | Arginin/lysin-angereicherte peptide | |
| Surai et al. | Silymarin and immunity | |
| Van Der Merwe | Tumour necrosis factor | |
| Zhang et al. | Combined therapy of interleukin-12 and interleukin-18 against Cryptococcus neoformans infection in a murine model | |
| Tamura et al. | Evaluation of recombinant human tumor necrosis factor by scheduled intratumoral administration in mice bearing transplantable tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20140813 |